130 lines
No EOL
27 KiB
XML
130 lines
No EOL
27 KiB
XML
<?xml version="1.0" encoding="utf-8"?>
|
|
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
|
|
|
|
<head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
|
|
<!-- AppResources meta begin -->
|
|
<meta name="paf-app-resources" content="" />
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- AppResources meta end -->
|
|
|
|
<!-- TemplateResources meta begin -->
|
|
<meta name="paf_template" content="" />
|
|
|
|
<!-- TemplateResources meta end -->
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548865" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="printable" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548865/?report=printable" /><meta name="ncbi_app" content="bookshelf" />
|
|
<!-- Logger end -->
|
|
|
|
<title>Clobazam - LiverTox - NCBI Bookshelf</title>
|
|
|
|
<!-- AppResources external_resources begin -->
|
|
<link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>
|
|
|
|
<!-- AppResources external_resources end -->
|
|
|
|
<!-- Page meta begin -->
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Clobazam" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2017/01/25" /><meta name="citation_pmid" content="31644172" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548865/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Clobazam" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2017/01/25" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548865/" /><meta name="description" content="Clobazam is a benzodiazepine that is used as an anticonvulsant in the therapy of severe childhood epilepsy. Therapy with clobazam has not been associated with serum aminotransferase elevations, and clinically apparent liver injury from clobazam has yet to be reported and must be rare, if it occurs at all." /><meta name="og:title" content="Clobazam" /><meta name="og:type" content="book" /><meta name="og:description" content="Clobazam is a benzodiazepine that is used as an anticonvulsant in the therapy of severe childhood epilepsy. Therapy with clobazam has not been associated with serum aminotransferase elevations, and clinically apparent liver injury from clobazam has yet to be reported and must be rare, if it occurs at all." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548865/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Clobazam/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548865/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_print.min.css" type="text/css" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} </style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.26/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.26/books.min.js"> </script>
|
|
|
|
<!-- Page meta end -->
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8B28D77D7C25B1000000000078005B.m_5" />
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4216701/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3984801/12930/3964959.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3411343/3882866.css" media="print" /></head>
|
|
<body class="book-part">
|
|
<div class="grid no_max_width">
|
|
<div class="col twelve_col nomargin shadow">
|
|
<!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
|
|
<div class="sysmessages">
|
|
<noscript>
|
|
<p class="nojs">
|
|
<strong>Warning:</strong>
|
|
The NCBI web site requires JavaScript to function.
|
|
<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
|
|
</p>
|
|
</noscript>
|
|
</div>
|
|
<!--/.sysmessage-->
|
|
<div class="wrap">
|
|
<div class="page">
|
|
<div class="top">
|
|
|
|
<div class="header">
|
|
|
|
|
|
</div>
|
|
|
|
|
|
|
|
<!--<component id="Page" label="headcontent"/>-->
|
|
|
|
</div>
|
|
<div class="content">
|
|
<!-- site messages -->
|
|
<div class="container content">
|
|
<div class="document">
|
|
<div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div></div></div>
|
|
<div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548865_"><span class="title" itemprop="name">Clobazam</span></h1><p class="small">Last Update: <span itemprop="dateModified">January 25, 2017</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Clobazam.OVERVIEW"><h2 id="_Clobazam_OVERVIEW_">OVERVIEW</h2><div id="Clobazam.Introduction"><h3>Introduction</h3><p>Clobazam is a benzodiazepine that is used as an anticonvulsant in the therapy of severe childhood epilepsy. Therapy with clobazam has not been associated with serum aminotransferase elevations, and clinically apparent liver injury from clobazam has yet to be reported and must be rare, if it occurs at all.</p></div><div id="Clobazam.Background"><h3>Background</h3><p>Clobazam (kloe' ba zam) is a unique 1,5 benzodiazepine which is used in the United States as an anticonvulsant, but is available in other countries for therapy of anxiety as well as epilepsy. The anticonvulsant activity of clobazam appears to be mediated by its ability to enhance gamma-aminobutyric acid (GABA) medicated inhibition of synaptic transmission via binding to the GABA-A receptor. Clobazam was approved for use in the United States in 2011 as an anticonvulsant to be used either alone or in combination with other agents as therapy of the severe form of childhood epilepsy known as Lennox-Gastaut syndrome. Clobazam is available in tablets of 5, 10 and 20 mg under the brand name Onfi in the United States and Frisium and Urbanol elsewhere. The recommended initial dose is 5 mg once or twice daily, with subsequent increases to a usual maintenance dose of 20 mg twice daily. The dose should be increased and tapered gradually. The most common side effects are dose related and include dizziness, somnolence, impaired concentration, nervousness, aggression, antegrade amnesia, headache, fatigue, nausea and weakness. Clobazam can also lead to physical dependence and sudden discontinuation can cause withdrawal symptoms and rebound seizure activity.</p></div><div id="Clobazam.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>Limited data are available on the hepatotoxicity of clobazam. In clinical trials, clobazam was not associated with an increased frequency of serum aminotransferase elevations as compared to placebo treatment, and there were no instances of clinically apparent liver injury. No individual case reports of clobazam hepatotoxicity have been published since its wide spread clinical availability. Liver injury from benzodiazepines is quite rare, but isolated instances of hepatotoxicity have been reported for clorazepate and clonazepam, two other benzodiazepines used predominantly in the therapy of epilepsy. Thus, clinically apparent liver injury due to clobazam must be rare, if it occurs at all.</p><p>Likelihood score: E (unlikely cause of clinically apparent liver injury).</p></div><div id="Clobazam.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>Clobazam is extensively metabolized by the liver, largely by glucuronidation and acetylation. Its metabolism is independent of the microsomal P450 system, and it has little or no effect on P450 activity and lacks significant drug-drug interactions.</p></div><div id="Clobazam.Outcome_and_Management"><h3>Outcome and Management</h3><p>There is no information on the possible cross sensitivity to hepatotoxicity among the various benzodiazepines used as anticonvulsants such as diazepam, clonazepam, clorazepate or clobazam. Nevertheless, switching from one to another after clinically apparent liver injury should be done with caution and with appropriate clinical monitoring.</p><p>Drug Class: <a href="/books/n/livertox/Anticonvulsants/">Anticonvulsants</a>, <a href="/books/n/livertox/BenzodiazepineDrugs/">Benzodiazepines</a></p></div></div><div id="Clobazam.PRODUCT_INFORMATION"><h2 id="_Clobazam_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><div id="Clobazam.BPI" class="box"><p>
|
|
<b>REPRESENTATIVE TRADE NAMES</b>
|
|
</p><p>Clobazam – Onfi®</p><p>
|
|
<b>DRUG CLASS</b>
|
|
</p><p>Anticonvulsants</p><p>
|
|
<a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Clobazam" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">COMPLETE LABELING</a>
|
|
</p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div></div><div id="Clobazam.CHEMICAL_FORMULAS_AND_STRUCTURE"><h2 id="_Clobazam_CHEMICAL_FORMULAS_AND_STRUCTURE_">CHEMICAL FORMULAS AND STRUCTURES</h2><div id="Clobazam.T1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548865/table/Clobazam.T1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Clobazam.T1_lrgtbl__"><table><thead><tr><th id="hd_h_Clobazam.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">DRUG</th><th id="hd_h_Clobazam.T1_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">CAS REGISTRY NO.</th><th id="hd_h_Clobazam.T1_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Clobazam.T1_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Clobazam.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Clobazam</td><td headers="hd_h_Clobazam.T1_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/134994740" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">22316-47-8</a>
|
|
</td><td headers="hd_h_Clobazam.T1_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">C16-H13-Cl-N2-O2</td><td headers="hd_h_Clobazam.T1_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<div class="graphic"><img src="/books/NBK548865/bin/Clobazam_structure.jpg" alt="Clobazam chemical structure" /></div>
|
|
</td></tr><tr><td headers="hd_h_Clobazam.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Clonazepam</td><td headers="hd_h_Clobazam.T1_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/134979678" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">1622-61-3</a>
|
|
</td><td headers="hd_h_Clobazam.T1_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">C15-H10-Cl-N3-O3</td><td headers="hd_h_Clobazam.T1_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<div class="graphic"><img src="/books/NBK548865/bin/Clonazepam_Structure.jpg" alt="Clonazepam chemical structure" /></div>
|
|
</td></tr><tr><td headers="hd_h_Clobazam.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Clorazepate</td><td headers="hd_h_Clobazam.T1_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/135004253" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">57109-90-7</a>
|
|
</td><td headers="hd_h_Clobazam.T1_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">C16-H10-Cl-N4-O3.K.H-K-O</td><td headers="hd_h_Clobazam.T1_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<div class="graphic"><img src="/books/NBK548865/bin/Clorazepate_Structure.jpg" alt="Clorazepate chemical structure" /></div>
|
|
</td></tr><tr><td headers="hd_h_Clobazam.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Diazepam</td><td headers="hd_h_Clobazam.T1_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/134974836" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">439-14-5</a>
|
|
</td><td headers="hd_h_Clobazam.T1_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">C16-H13-Cl-N2-O</td><td headers="hd_h_Clobazam.T1_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<div class="graphic"><img src="/books/NBK548865/bin/Diazepam_Structure.jpg" alt="Diazepam chemical structure" /></div>
|
|
</td></tr></tbody></table></div></div></div><div id="Clobazam.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Clobazam_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 25 January 2017</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Clobazam.R1">Zimmerman HJ. Anticonvulsants. In, Zimmerman, HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999: pp. 498-516.<div><i>(Expert review of anticonvulsants and liver injury published in 1999; diazepam, but not clobazam is discussed).</i></div></div></li><li><div class="bk_ref" id="Clobazam.R2">Pirmohamed M, Leeder SJ. Anticonvulsant agents. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013: pp 423-42.<div><i>(Review of anticonvulsant induced liver injury; clobazam is not discussed).</i></div></div></li><li><div class="bk_ref" id="Clobazam.R3">McNamara JO. Pharmacology of the epilepsies. In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman & Gilman’s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 583-607.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="Clobazam.R4">Jacobson AF, Goldstein BJ, Dominguez RA, Steinbook RM. A placebo-controlled, double-blind comparison of clobazam and diazepam in the treatment of anxiety. J Clin Psychiatry 1983; 44: 296-300. [<a href="https://pubmed.ncbi.nlm.nih.gov/6135690" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6135690</span></a>]<div><i>(Controlled trial of 4 weeks of diazepam vs clobazam vs placebo in 114 patients with anxiety found sedation similar with either drug, but dizziness more frequent with diazepam; no mention of ALT elevations or hepatotoxicity, although ALT was measured at the start and end of therapy).</i></div></div></li><li><div class="bk_ref" id="Clobazam.R5">Clobazam in treatment of refractory epilepsy: the Canadian experience. A retrospective study. Canadian Clobazam Cooperative Group. Epilepsia 1991; 32: 407-16. [<a href="https://pubmed.ncbi.nlm.nih.gov/2044502" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2044502</span></a>]<div><i>(Retrospective survey of Canadian neurologists with experience using clobazam in refractory epilepsy in a total of 877 patients; 32% had adverse events, most commonly somnolence, dizziness, ataxia, mood changes, hostility, blurred vision and weight gain; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Clobazam.R6">Conry JA, Ng YT, Paolicchi JM, Kernitsky L, Mitchell WG, Ritter FJ, Collins SD, Tracy K, et al. Clobazam in the treatment of Lennox-Gastaut syndrome. Epilepsia 2009; 50: 1158-66. [<a href="https://pubmed.ncbi.nlm.nih.gov/19170737" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19170737</span></a>]<div><i>(Among 68 children with Lennox-Gastaut syndrome who were treated with either low or high dose clobazam for 7 weeks, seizure reduction was more frequent with the higher dose as were side effects, which included somnolence, sedation, constipation, salivation, insomnia, irritability and lability; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Clobazam.R7">Ng YT, Conry JA, Drummond R, Stolle J, Weinberg MA; OV-1012 Study Investigators. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology. 2011; 77: 1473-81. [<a href="https://pubmed.ncbi.nlm.nih.gov/21956725" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21956725</span></a>]<div><i>(Among 238 patients with Lennox-Gastaut syndrome treated with one of 3 doses of clobazam or placebo for at least 18 weeks, no patient developed serious hepatic adverse events and there were no abnormal clinical laboratory results linked to clobazam therapy).</i></div></div></li><li><div class="bk_ref" id="Clobazam.R8">Clobazam (Onfi) for Lennox-Gastaut syndrome. Med Lett Drugs Ther 2012; 54 (1385): 18-9. [<a href="https://pubmed.ncbi.nlm.nih.gov/22382580" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22382580</span></a>]<div><i>(Concise review of the pharmacology, clinical efficacy, adverse events, drug interactions and costs of clobazam for Lennox-Gastaut syndrome shortly after its approval for this indication in the US; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Clobazam.R9">Yang LP, Scott LJ. Clobazam : in patients with Lennox-Gastaut syndrome. CNS Drugs 2012; 26: 983-91. [<a href="https://pubmed.ncbi.nlm.nih.gov/23034582" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23034582</span></a>]<div><i>(Summary of the structure, mechanism of action, pharmacology, clinical efficacy and safety of clobazam for Lennox Gastaut syndrome; no mention of hepatotoxicity or ALT elevations).</i></div></div></li><li><div class="bk_ref" id="Clobazam.R10">Ng YT, Conry J, Paolicchi J, Kernitsky L, Mitchell W, Drummond R, Isojarvi J, Lee D, Owen R; OV-1004 study investigators. Long-term safety and efficacy of clobazam for Lennox-Gastaut syndrome: interim results of an open-label extension study. Epilepsy Behav 2012; 25: 687-94. [<a href="https://pubmed.ncbi.nlm.nih.gov/23141144" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23141144</span></a>]<div><i>(Among 267 children and adults who participated in controlled trials of clobazam and were enrolled in a long term extension study, 13 discontinued therapy because of side effects and six died, but none were attributed to hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Clobazam.R11">Wheless JW, Phelps SJ. Clobazam: a newly approved but well-established drug for the treatment of intractable epilepsy syndromes. J Child Neurol 2013; 28: 219-29. [<a href="https://pubmed.ncbi.nlm.nih.gov/23112237" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23112237</span></a>]<div><i>(Review of the pharmacology, safety and efficacy of clobazam in Lennox Gastaut syndrome; no mention of hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Clobazam.R12">Drugs for epilepsy. Treat Guidel Med Lett 2013; 11: 9-18. [<a href="https://pubmed.ncbi.nlm.nih.gov/23348233" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23348233</span></a>]<div><i>(Concise review of indications and side effects of anticonvulsants; clobazam is approved only for treatment of severe seizures associated with Lennox-Gastaut syndrome; no mention of hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Clobazam.R13">Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013; 144: 1419-25. [<a href="https://pubmed.ncbi.nlm.nih.gov/23419359" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23419359</span></a>]<div><i>(In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period, but none of the 96, none were attributed to clobazam or other benzodiazepines).</i></div></div></li><li><div class="bk_ref" id="Clobazam.R14">Klehm J, Thome-Souza S, Sánchez Fernández I, Bergin AM, Bolton J, Harini C, Kadish NE, et al. Clobazam: effect on frequency of seizures and safety profile in different subgroups of children with epilepsy. Pediatr Neurol 2014; 51: 60-6. [<a href="https://pubmed.ncbi.nlm.nih.gov/24830765" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24830765</span></a>]<div><i>(Among 300 children with seizures treated with clobazam for more than 1 month at a single referral center, 28% became seizure free and the most common side effects were tiredness [15%] and mood or behavioral changes [8%]; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Clobazam.R15">Conry JA, Ng YT, Kernitsky L, Mitchell WG, Veidemanis R, Drummond R, Isojarvi J, Lee D, et al.; OV-1004 Study Investigators. Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years. Epilepsia 2014; 55: 558-67. [<a href="/pmc/articles/PMC4303987/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4303987</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24580023" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24580023</span></a>]<div><i>(Among 267 patients with Lennox-Gastaut syndrome enrolled in a long term, open label, observational study of clozabam, adverse events were similar to those in controlled trials and none of the serious adverse events or the 18 discontinuations because of side effects or the 10 deaths were attributed to liver injury).</i></div></div></li><li><div class="bk_ref" id="Clobazam.R16">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al.; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology 2015; 148: 1340-52. [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25754159" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 40 [4.5%] were attributed to anticonvulsants, but none to clobazam or other benzodiazepine anticonvulsants).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
|
|
<div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548865</span><span class="label">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/31644172" title="PubMed record of this page" ref="pagearea=meta&targetsite=entrez&targetcat=link&targettype=pubmed">31644172</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Clindamycin/" title="Previous page in this title">< Prev</a><a class="active page_link next" href="/books/n/livertox/Clofarabine/" title="Next page in this title">Next ></a></div></div></div></div>
|
|
|
|
</div>
|
|
</div>
|
|
</div>
|
|
<div class="bottom">
|
|
|
|
<div id="NCBIFooter_dynamic">
|
|
<!--<component id="Breadcrumbs" label="breadcrumbs"/>
|
|
<component id="Breadcrumbs" label="helpdesk"/>-->
|
|
|
|
</div>
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
</div>
|
|
</div>
|
|
<!--/.page-->
|
|
</div>
|
|
<!--/.wrap-->
|
|
</div><!-- /.twelve_col -->
|
|
</div>
|
|
<!-- /.grid -->
|
|
|
|
<span class="PAFAppResources"></span>
|
|
|
|
<!-- BESelector tab -->
|
|
|
|
|
|
|
|
<noscript><img alt="statistics" src="/stat?jsdisabled=true&ncbi_db=books&ncbi_pdid=book-part&ncbi_acc=NBK548865&ncbi_domain=livertox&ncbi_report=printable&ncbi_type=fulltext&ncbi_objectid=&ncbi_pcid=/NBK548865/?report=printable&ncbi_app=bookshelf" /></noscript>
|
|
|
|
|
|
<!-- usually for JS scripts at page bottom -->
|
|
<!--<component id="PageFixtures" label="styles"></component>-->
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal104 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3879255/4121861/3501987/4008961/3893018/3821238/3400083/3426610.js" snapshot="books"></script></body>
|
|
</html> |